Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor

Shanghai Acebright Pharmaceuticals

Status and phase

Unknown

Phase 1

Conditions

Malignant Advanced Solid Tumor

Treatments

Drug: Simmiparib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02993913

ACE-CT-006I

Details and patient eligibility

About

Phase I dose escalating trial. Primary objectives of this study are to assess the safety and tolerability of Simmiparib following single and multiple oral doses in patients with advanced solid malignancies, to determine the maximum tolerance dose (MTD) and dose limiting toxicity (DLT), and pharmacokinetic profile.

The Secondary objective is to observe the preliminary antitumor effect of Simmiparib.

Full description

This single-center, nonrandomized, open-label, dose-escalating study. The trial was divided into dose escalation and expansion stages.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients confirmed with advanced solid tumor based on pathology and/or cytology, considered unresponsive or poorly responsive to standard therapies, no curative therapies or can't tolerate standard therapies;
Patients must have measurable disease in accordance with RECIST criteria v. 1.1, at least one lesion that can be accurately measured in CT and MRI at least one dimension ( longest diameter≥10mm; if lymph node, short diameter≥15mm );
Age≥18 and ≤75 years, both men and women, no history of drug abuse and alcohol;
Life expectancy≥ 3 months and can be followed for safety and efficiency
Received no prior anti-tumor therapies at least within past 4 weeks and no other adjuvant anti-tumor regimen(including steroids mediations )
Have recovered to≤ common terminology criteria of adverse events (CTC-AE) 1 from toxicities of prior therapy
Not participated in any clinical trials within 28 days;
Not have received treatment of poly-ADP ribose polymerase (PARP) inhibitor;
No serious abnormal hematopoiesis function, has adequate cardiac, pulmonic, hepatic and renal function. Blood routine and blood biochemical examination within 2 weeks before enrollment : White blood cell (WBC) ≥4000/mm3, Absolute neutrophil count (ANC) ≥1,500/mm3, Platelets ≥100,000/mm3, Coagulation function ≤ 1.5 times upper limit of normal (ULN), serum creatinine ≤ 1.5 times ULN, Total bilirubin ≤ 1.5 times ULN, Patients without liver metastasis, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)≤ 2.5 times ULN; Patients with liver metastasis, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/≤ 2.5 times ULN, NYHAclass≤Ⅱand Left ventricular ejection fraction ( LVEF)>50%;
Virology test: negative HbsAg, HCV, HIV and syphilis
Eastern Cooperative Oncology Group(ECOG) performance status ≤2;
No history of other malignant tumors, except cervical carcinoma in situ, basal skin cancer or squamous-cell carcinoma that have been cured; No other serious illnesses that are in conflict with this study and significant heart disease and psychosis;
Ability to understand and a willingness to sign a written informed consent; Obtaining consent before any operation

Exclusion criteria

Patients with serious medical disease, including, severe cardiopathy, vascular disease, uncontrolled diabetes, uncontrolled hypertension, severe infection , or psychosis, etc.;
Patients with primary brain lesion or metastases lesion;
Female patient who is pregnant, breast feeding or unwilling to contraception;
Patient who received or is receiving any other investigational agents within 4 weeks prior to treatment;
Patients, with poor compliance, or based on the opinion of the investigator, should not be enrolled into this study;
has not recovered to grade 1 or better from any adverse events related to previous therapy.
Neurotoxicity observed in previous antineoplastic therapy has not recovered to grade 1 or below.